<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8739">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809523</url>
  </required_header>
  <id_info>
    <org_study_id>0810004322</org_study_id>
    <nct_id>NCT00809523</nct_id>
  </id_info>
  <brief_title>A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)</brief_title>
  <official_title>A Multicenter, Randomized Controlled Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Litebook Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Associates Research, Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled clinical trial of inactivated negative ion generation or
      light-emitting photodiode therapy for Seasonal Affective Disorder (SAD, winter depression),
      for subjects with a DSM IV diagnosis of Major Depression, with Seasonal Pattern, Winter
      type, to examine efficacy of treatments for this condition. The trial has a 1 week baseline
      phase and a 4 week treatment phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled clinical trial comparing an inactivated negative ion
      generation (placebo condition) and light-emitting photodiode therapy (active condition), for
      Seasonal Affective Disorder (SAD, winter depression), for subjects with a DSM IV diagnosis
      of Major Depression, with Seasonal Pattern, Winter type, to examine efficacy of treatments
      for this condition. Exclusion criteria included any other current treatment for SAD, as well
      as bipolar disorder, type 1, a chronic psychotic disorder, or a substance use not if full
      remission for at least one year. The trial has a 1 week baseline phase and subjects were
      seen weekly during a 4 week treatment phase. The study was double-blind. The study was
      conducted at 8 sites in the US, Canada and The Netherlands.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage Change SIGH SAD Depression Rating</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>SIGH SAD Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorder (SAD)version. The items are augmented with additional items to reflect better the atypical depressive symptoms usually seen in SAD, eg, increased sleep, weight, appetite and fatigue. On this scale, higher scores reflect increased depression intensity. The maximum score attainable is 63, and the minimum is 0. A score of less than 9 is regarded as consistent with normal mood, the absence of major depression.
Calculated: SIGH SAD score at trial end - SIGH SAD score at randomization x 100 / SIGH SAD score at randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SIGH SAD Depression Rating</measure>
    <time_frame>Weekly</time_frame>
    <safety_issue>No</safety_issue>
    <description>SIGH SAD Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorder (SAD)version. This is a structured interview, which is an interview in which the clinician is provided exact questions to use to inquire about symptoms of depression and explicit standards for rating the intensity of each symptom item. The interview assesses the symptoms which make up the Hamilton Depression Rating Scale, which is the standard in the majority of clinical trials in depression. The items are augmented with additional items to reflect better the atypical depressive symptoms usually seen in SAD, eg, increased sleep, weight, appetite and fatigue. On this scale, higher scores reflect increased depression intensity. The maximum score attainable is 63, and the minimum is 0. A score of less than 9 is regarded as consistent with normal mood, the absence of major depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Severity</measure>
    <time_frame>Randomization and at 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Clinical Global Impression of Severity is a 7-point scale in which the clinician gives an overall impression of depression severity, with the following anchor points: (1)Normal, not at all ill, (2)Borderline ill, (3) Mildly ill, (4)Moderately ill, (5) Markedly ill, (6)Severely ill, and (7)Among the most severely ill patients. The minimum is therefore 1 and the maximum is 7, which represents very severe depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Seasonal Affective Disorder</condition>
  <arm_group>
    <arm_group_label>Inactivated negative ion generator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Equivalent exposure to inactivated Negative Ion Generator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LED light treatment device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Light-emitting photodiode light treatment device, used for 30 min before 8 am</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Negative Ion Generator</intervention_name>
    <description>Equivalent exposure to inactivated Negative Ion Generator</description>
    <arm_group_label>Inactivated negative ion generator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light-emitting Photodiode light treatment device</intervention_name>
    <description>Light-emitting Photodiode light treatment device, used for 30 min before 8 am</description>
    <arm_group_label>LED light treatment device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Seasonal Affective Disorder

          -  Age 18 to 65

        Exclusion Criteria:

          -  Psychotropic medication treatment

          -  History of light treatment for SAD

          -  History of mania or psychosis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Desan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raymond Lam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia, Vancouver, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Clinical Research Associates</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLean Hospital/Harvard</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Regional Hospital</name>
      <address>
        <city>St. John</city>
        <state>New Brunswick</state>
        <zip>E2l 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAMH/University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sleep and Alertness Inc</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <state>RB</state>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 29, 2013</lastchanged_date>
  <firstreceived_date>December 16, 2008</firstreceived_date>
  <firstreceived_results_date>September 7, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAD</keyword>
  <keyword>winter depression</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mood Disorders</mesh_term>
    <mesh_term>Seasonal Affective Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inactivated Negative Ion Generator</title>
          <description>Equivalent exposure to inactivated Negative Ion Generator</description>
        </group>
        <group group_id="P2">
          <title>LED Phototherapy Device</title>
          <description>Light-emitting photodiode light treatment device, used for 30 min before 8 am</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inactivated Negative Ion Generator</title>
          <description>Equivalent exposure to inactivated Negative Ion Generator</description>
        </group>
        <group group_id="B2">
          <title>LED Phototherapy Device</title>
          <description>Light-emitting photodiode light treatment device, used for 30 min before 8 am</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
                <measurement group_id="B2" value="52"/>
                <measurement group_id="B3" value="106"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
                <measurement group_id="B2" value="52"/>
                <measurement group_id="B3" value="106"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="42"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="80"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="18"/>
                <measurement group_id="B3" value="38"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Netherlands</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="51"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>SIGH SAD Depression Rating</title>
        <description>SIGH SAD Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorder (SAD)version. This is a structured interview, which is an interview in which the clinician is provided exact questions to use to inquire about symptoms of depression and explicit standards for rating the intensity of each symptom item. The interview assesses the symptoms which make up the Hamilton Depression Rating Scale, which is the standard in the majority of clinical trials in depression. The items are augmented with additional items to reflect better the atypical depressive symptoms usually seen in SAD, eg, increased sleep, weight, appetite and fatigue. On this scale, higher scores reflect increased depression intensity. The maximum score attainable is 63, and the minimum is 0. A score of less than 9 is regarded as consistent with normal mood, the absence of major depression.</description>
        <time_frame>Weekly</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat analysis last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Negative Ion Generator</title>
            <description>Equivalent exposure to inactivated Negative Ion Generator</description>
          </group>
          <group group_id="O2">
            <title>LED Phototherapy Device</title>
            <description>Light-emitting photodiode light treatment device, used for 30 min before 8 am</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>SIGH SAD Depression Rating</title>
            <description>SIGH SAD Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorder (SAD)version. This is a structured interview, which is an interview in which the clinician is provided exact questions to use to inquire about symptoms of depression and explicit standards for rating the intensity of each symptom item. The interview assesses the symptoms which make up the Hamilton Depression Rating Scale, which is the standard in the majority of clinical trials in depression. The items are augmented with additional items to reflect better the atypical depressive symptoms usually seen in SAD, eg, increased sleep, weight, appetite and fatigue. On this scale, higher scores reflect increased depression intensity. The maximum score attainable is 63, and the minimum is 0. A score of less than 9 is regarded as consistent with normal mood, the absence of major depression.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Randomization</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28.6" spread="6.7"/>
                  <measurement group_id="O2" value="27.7" spread="4.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23.6" spread="8.7"/>
                  <measurement group_id="O2" value="20.9" spread="7.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.9" spread="9.3"/>
                  <measurement group_id="O2" value="17.4" spread="7.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18.6" spread="9.7"/>
                  <measurement group_id="O2" value="15.8" spread="8.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17.9" spread="10.2"/>
                  <measurement group_id="O2" value="13.3" spread="9.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression of Severity</title>
        <description>The Clinical Global Impression of Severity is a 7-point scale in which the clinician gives an overall impression of depression severity, with the following anchor points: (1)Normal, not at all ill, (2)Borderline ill, (3) Mildly ill, (4)Moderately ill, (5) Markedly ill, (6)Severely ill, and (7)Among the most severely ill patients. The minimum is therefore 1 and the maximum is 7, which represents very severe depression.</description>
        <time_frame>Randomization and at 4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>intent to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Negative Ion Generator</title>
            <description>Equivalent exposure to inactivated Negative Ion Generator</description>
          </group>
          <group group_id="O2">
            <title>LED Phototherapy Device</title>
            <description>Light-emitting photodiode light treatment device, used for 30 min before 8 am</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Global Impression of Severity</title>
            <description>The Clinical Global Impression of Severity is a 7-point scale in which the clinician gives an overall impression of depression severity, with the following anchor points: (1)Normal, not at all ill, (2)Borderline ill, (3) Mildly ill, (4)Moderately ill, (5) Markedly ill, (6)Severely ill, and (7)Among the most severely ill patients. The minimum is therefore 1 and the maximum is 7, which represents very severe depression.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Randomization</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.2" spread="0.6"/>
                  <measurement group_id="O2" value="4.2" spread="0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" spread="1.3"/>
                  <measurement group_id="O2" value="2.4" spread="1.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Data were analyzed at the follow up timepoint (4 weeks) to test for differences between the experimental groups.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change SIGH SAD Depression Rating</title>
        <description>SIGH SAD Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorder (SAD)version. The items are augmented with additional items to reflect better the atypical depressive symptoms usually seen in SAD, eg, increased sleep, weight, appetite and fatigue. On this scale, higher scores reflect increased depression intensity. The maximum score attainable is 63, and the minimum is 0. A score of less than 9 is regarded as consistent with normal mood, the absence of major depression.
Calculated: SIGH SAD score at trial end – SIGH SAD score at randomization x 100 / SIGH SAD score at randomization</description>
        <time_frame>4 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent to treat analysis last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Inactivated Negative Ion Generator</title>
            <description>Equivalent exposure to inactivated Negative Ion Generator</description>
          </group>
          <group group_id="O2">
            <title>LED Phototherapy Device</title>
            <description>Light-emitting photodiode light treatment device, used for 30 min before 8 am</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage Change SIGH SAD Depression Rating</title>
            <description>SIGH SAD Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorder (SAD)version. The items are augmented with additional items to reflect better the atypical depressive symptoms usually seen in SAD, eg, increased sleep, weight, appetite and fatigue. On this scale, higher scores reflect increased depression intensity. The maximum score attainable is 63, and the minimum is 0. A score of less than 9 is regarded as consistent with normal mood, the absence of major depression.
Calculated: SIGH SAD score at trial end – SIGH SAD score at randomization x 100 / SIGH SAD score at randomization</description>
            <units>percentage of change on SIGH SAD</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-36.4" spread="34.9"/>
                  <measurement group_id="O2" value="-52.7" spread="31.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.014</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Inactivated Negative Ion Generator</title>
          <description>Equivalent exposure to inactivated Negative Ion Generator</description>
        </group>
        <group group_id="E2">
          <title>LED Phototherapy Device</title>
          <description>Light-emitting photodiode light treatment device, used for 30 min before 8 am</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Eye strain/glare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Desan, MD, PhD</name_or_title>
      <organization>Yale University</organization>
      <phone>203 785 2618</phone>
      <email>paul.desan@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
